S. Moe

4 ta ish

Médecins Sans Frontières, Amsterdam, the Netherlands

1. Primary bedaquiline resistance in Karakalpakstan, Uzbekistan

   S. Moe, M. L. Rekart, D. Hernandez +9

   MaqolaTuberculosis Research and EpidemiologyThe International Journal of Tuberculosis and Lung Disease20231 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.281628

2. How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial

   Ilaria Motta, Martina Cusinato, Andrew Ludman +15

   MaqolaCardiac electrophysiology and arrhythmiasAntimicrobial Agents and Chemotherapy20240 iqtibos

   ABIABI:AkademIndex/openalex/2024.article.000869

3. Second-line drug-resistant TB and associated risk factors in Karakalpakstan, Uzbekistan

   S. Moe, I. Azamat, Sholpan Allamuratova +14

   MaqolaTuberculosis Research and EpidemiologyIJTLD OPEN20240 iqtibos

   ABIABI:AkademIndex/openalex/2024.article.001030

4. The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)–Based Regimens for Rifampicin-Resistant Tuberculosis in Non-Trial Settings—A Prospective Cohort Study in Belarus and Uzbekistan

   Animesh A. Sinha, Robert J. Klebe, Michael L. Rekart +22

   MaqolaTuberculosis Research and EpidemiologyClinical Infectious Diseases20250 iqtibos

   ABIABI:AkademIndex/openalex/2025.article.000230